Search
WCLC: Hold you HARMONis: Keytruda safe from Summit
Despite the recent large PD1 beat by Summit/Akeso’s ivonescimab (SMT112) versus gold standard Keytruda [MRK] in lung cancer at WCLC24, our unique analysis reveals why we do not share the markets optimism by raising several concerns about replacing the Keytruda standard of care in US/EMA and continue to see Keytruda’s Lung cancer franchise intact.
Comments